| [1] |
Wakasugi S, Teshima H, Nakamura H, et al. Tc-99m MIBI localization in bone marrow:a marker of bone marrow malignancy[J]. Clin Nucl Med, 1998, 23(10):664.
|
| [2] |
Jonsson C, Jacobsson H. Accumulation of 99mTc-MIBI in bone marrow[J]. Ann Nucl Med, 1996, 10(3):281-285.
|
| [3] |
Wakasugi S, Ohta K, Hasegawa Y, et al. Detection of minimal residual disease in acute leukemia by Tc-99m MIBI femoral marrow imaging[J]. Clin Nucl Med, 2001, 26(4):325-330.
|
| [4] |
Teodori E, Dei S, Scapecchi S, et al. The medicinal chemistry of multidrug resistance (MDR) reversing drugs[J]. Farmaco, 2002, 57(5):385-415.
|
| [5] |
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:role of ATP-dependent transporters[J]. Nat Rev Cancer, 2002, 2(1):48-58.
|
| [6] |
Mubashar M, Harrington K, Chaudhary K, et al. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer[J]. J Nucl Med, 2002, 43(4):519-525.
|
| [7] |
Kao A, Shiun SC, Hsu NY, et al. Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cance. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression[J]. Ann Oncol, 2001, 12(11):1561-1566.
|
| [8] |
Burak Z, Ersoy O, Moretti J, et al. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 over expression in patients with musculoskeletal sarcomas:comparison with therapy response[J]. Eur J Nucl Med, 2001, 28(9):1341-1350.
|
| [9] |
Ak I, Asian V, Vardareli E, et al. Assessment of the P-glycoprotein expression by 99mTc-MIBI bone marrow imaging in patients with untreated leukemia[J]. Nucl Med Commun, 2003, 24(4):397-402.
|
| [10] |
Belhaj-Tayeb H, Briane D, Vergote J, et al. In vitro and in vivo study of 99mTc-MIBI encapsulated in PEG-liposomes:a promising radiotracer for tumor imaging[J]. Eur J Nucl Med Mol Imaging, 2003, 30(4):502-509.
|